Literature DB >> 15448188

Certain 1,4-disubstituted aromatic piperidines and piperazines with extreme selectivity for the dopamine D4 receptor interact with a common receptor microdomain.

Sandhya Kortagere1, Peter Gmeiner, Harel Weinstein, John A Schetz.   

Abstract

We previously demonstrated that, in the D4 dopamine receptor, the aromatic microdomain that spans the interface of the second and third transmembrane segments influences the high-affinity interactions with the D4-selective ligand L750,667 [3-[[4-(4-iodophenyl) piperazin-1-yl]methyl]-1H-pyrrolo[2,3-b]pyridine] and the D2-selective ligands methylspiperone, aripiprazole, and its congener OPC4392 [7-[3-(4-(2,3-dimethylphenyl) piperazinyl) propoxy] 2-(1H)-quinolinone] (Schetz et al., 2000). Here we tested a variety of 1,4-disubstituted aromatic piperidines/piperazines (1,4-DAPs) with different subtype selectivities and functional properties against a panel of D4 receptor mutations in the aromatic microdomain to ascertain whether these ligands recognize this common site. Mutant D4 receptors were constructed by substituting the nonconserved amino acid(s) from the corresponding locations in the D2 receptor. The D4-L2.60W, D4-F2.61V, and D4-LM3.28-3.29FV substitutions result in alterations of the relative position of members of the aromatic microdomain. From these results and molecular models of the ligand-receptor complexes, we conclude that 9 of the 11 D4-selective 1,4-DAPs, including L750,667, have a common pattern of ligand-receptor recognition that depends upon favorable interactions with the phenylalanine at position 2.61 (D4-F2.61V, 20-96-fold decrease). Like methylspiperone, aripiprazole, and OPC4392, the two D4-selective 1,4-DAPs that are insensitive to the D4-F2.61V mutation are sensitive to aromatics at position 2.60 (D4-L2.60W, 7-20-fold increase), and they all have longer spacer arms that permit their tethered aromatics to adopt alternative orientations in the binding-site crevice. All 11 of the D4-selective 1,4-DAPs were sensitive to the D4-LM3.28-3.29FV mutation (13-494-fold decrease) but not the moderately D2-selective methylspiperone. The inferences suggest that subtype selectivity involves two different modes of interaction with the microdomain for the D4-selective 1,4-DAPs and a third mode for D2-selective 1,4-DAPs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15448188     DOI: 10.1124/mol.104.001321

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  14 in total

1.  Development and application of hybrid structure based method for efficient screening of ligands binding to G-protein coupled receptors.

Authors:  Sandhya Kortagere; William J Welsh
Journal:  J Comput Aided Mol Des       Date:  2006-10-13       Impact factor: 3.686

2.  Design, synthesis, radiolabeling, and in vivo evaluation of carbon-11 labeled N-[2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]ethyl]-3-methoxybenzamide, a potential positron emission tomography tracer for the dopamine D(4) receptors.

Authors:  Enza Lacivita; Paola De Giorgio; Irene T Lee; Sean I Rodeheaver; Bryan A Weiss; Claudia Fracasso; Silvio Caccia; Francesco Berardi; Roberto Perrone; Ming-Rong Zhang; Jun Maeda; Makoto Higuchi; Tetsuya Suhara; John A Schetz; Marcello Leopoldo
Journal:  J Med Chem       Date:  2010-10-28       Impact factor: 7.446

Review 3.  What can crystal structures of aminergic receptors tell us about designing subtype-selective ligands?

Authors:  Mayako Michino; Thijs Beuming; Prashant Donthamsetti; Amy Hauck Newman; Jonathan A Javitch; Lei Shi
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

4.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

5.  Homology Model Versus X-ray Structure in Receptor-based Drug Design: A Retrospective Analysis with the Dopamine D3 Receptor.

Authors:  Nicolas Levoin; Thierry Calmels; Stéphane Krief; Denis Danvy; Isabelle Berrebi-Bertrand; Jeanne-Marie Lecomte; Jean-Charles Schwartz; Marc Capet
Journal:  ACS Med Chem Lett       Date:  2011-02-11       Impact factor: 4.345

6.  Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes.

Authors:  David F Cummings; Diana C Canseco; Pratikkumar Sheth; James E Johnson; John A Schetz
Journal:  Bioorg Med Chem       Date:  2010-05-15       Impact factor: 3.641

7.  Transmembrane segment five serines of the D4 dopamine receptor uniquely influence the interactions of dopamine, norepinephrine, and Ro10-4548.

Authors:  David F Cummings; Spencer S Ericksen; Angela Goetz; John A Schetz
Journal:  J Pharmacol Exp Ther       Date:  2010-03-09       Impact factor: 4.030

Review 8.  The importance of discerning shape in molecular pharmacology.

Authors:  Sandhya Kortagere; Matthew D Krasowski; Sean Ekins
Journal:  Trends Pharmacol Sci       Date:  2009-01-31       Impact factor: 14.819

9.  A prototypical Sigma-1 receptor antagonist protects against brain ischemia.

Authors:  John A Schetz; Evelyn Perez; Ran Liu; Shiuhwei Chen; Ivan Lee; James W Simpkins
Journal:  Brain Res       Date:  2007-09-12       Impact factor: 3.252

10.  Ligand selectivity of D2 dopamine receptors is modulated by changes in local dynamics produced by sodium binding.

Authors:  Spencer S Ericksen; David F Cummings; Harel Weinstein; John A Schetz
Journal:  J Pharmacol Exp Ther       Date:  2008-10-10       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.